Report of Foreign Issuer (6-k)
February 10 2020 - 7:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2020
Commission File Number 001-38370
CollPlant Biotechnologies Ltd.
(Exact name of registrant as specified in
its charter)
4 Oppenheimer
St, Weizmann Science Park
Rehovot 7670104, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
This Report on Form 6-K and the
second and fourth paragraphs and “Forward-Looking Statements” of the press release attached to this Form 6-K are
hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163) and
Form F-3 (File No. 333-229486 and 333-228054), to be a part thereof from the date on which this report is submitted, to the
extent not superseded by documents or reports subsequently filed or furnished.
On February 6, 2020, the Board of Directors
of CollPlant Biotechnologies Ltd. (the “Company”) appointed Roger
J. Pomerantz, M.D., F.A.C.P, as the new Chairman of the Board, effective
immediately.
In connection
with the appointment of Dr. Pomerantz, on February 7, 2020, the Company and Dr. Pomerantz entered into a Chairman Services
Agreement (the “Agreement”), the terms of which are subject to shareholder approval. Under the Agreement, Dr.
Pomerantz shall be entitled to an annual fee of approximately $175,000, to be paid on a monthly basis and
options to purchase 162,713 ordinary shares (represented by 162,713 ADSs) exercisable at $11.06 per ADS. The options will
vest over four years, in accordance with the Company’s compensation policy. Dr. Pomerantz’s
engagement is terminable by either Dr. Pomerantz or the Company on thirty
days’ prior written notice other than in the case of a termination for cause. The Agreement also contains a non-compete
obligation for a period of six months following termination of his engagement, and customary provisions regarding
confidentiality of information, and assignment of inventions.
On February 10, 2020, the Company
issued a press release entitled “CollPlant Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P. as Chairman of
the Board of Directors.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference
herein.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
COLLPLANT BIOTECHNOLOGIES LTD.
|
|
|
|
Date: February 10, 2020
|
By:
|
/s/ Eran Rotem
|
|
|
Name: Eran Rotem
|
|
|
Title: Deputy CEO and Chief Financial Officer
|
2
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Apr 2023 to Apr 2024